Observational Study to Evaluate Efficacy, Safety and Tolerability of Z-n-butylresorcinol in Patients with Melasma
Phase 4
Completed
- Conditions
- Health Condition 1: null- Melasma
- Registration Number
- CTRI/2015/04/005697
- Lead Sponsor
- Micro Labs Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
•Subjects with melasma who are either treatment naive or were not on any treatment for at-least 6 months
•Subjects aged 18 and above years with melasma
•Subjects with Epidermal type of melasma
•Subjects with Fitzpatrick skin types III, IV and V
•Subjects willing to apply sunscreen during the course of study
•Subjects willing to return for all clinic visits and complete all study-related procedures
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluate the efficacy of 4-n-butylresorcinol in reducing melasmaTimepoint: 4th week and 8th Week
- Secondary Outcome Measures
Name Time Method Evaluate safety of 4-n-butylresorcinol based on the adverse effects as mentioned by the patient and evaluated by the investigator. <br/ ><br>Assess tolerability of 4-n-butylresorcinol by the investigators <br/ ><br>Timepoint: 8 weeks